Navigation Links
InnoPharma Completes $15 Million Series A Financing
Date:12/1/2011

PISCATAWAY, N.J., Dec. 1, 2011 /PRNewswire/ -- InnoPharma, Inc., a developer of sterile generic and specialty pharmaceutical products, announced that it has completed a $15 million Series A round of private financing. This financing was led by Thomas, McNerney & Partners.

"We are very pleased that InnoPharma's aggressive and well-managed growth over the last few years has allowed us to attract an outstanding investor, whose expertise and professional network will add tremendous value to InnoPharma," stated Navneet Puri, Ph.D., Founder, President, and Chief Executive Officer of InnoPharma. "The funds raised in this financing will allow us to accelerate the development of our product pipeline and also maximize the value that we offer to our customers and end users."

As a result of the financing, two new members have joined InnoPharma's board of directors: Alex Zisson and James Thomas, both partners at Thomas, McNerney & Partners.  The new board of directors will also include Navneet Puri, Raman Kapur, the former CEO of Warrick Pharmaceuticals, and Peter Werth, the CEO of ChemWerth.

"We're very excited to be partnering with InnoPharma.  The company's track record of FDA filings, approvals and partnerships is very impressive, and the additional resources will help InnoPharma maximize the true potential of its pipeline," said Alex Zisson.

Ledgemont Capital Group, LLC, served as the company's placement agent, and Lowenstein Sandler PC served as the company's legal counsel. Thomas, McNerney & Partners was represented by Goodwin Procter LLP.

About INNOPHARMA:

INNOPHARMA is a developer of sterile generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA
'/>"/>

SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Biocartis Completes EUR 71 Million (USD 100 Million) Series C Fund Raising
2. Agendia Successfully Completes Bi-Annual FDA Inspection
3. HeartWare Completes GLP Studies of Next Generation MVAD® Pump; Data Presented Today at ISRBP Congress
4. Enterologics Completes Acquisition of BioBalance Corp and Probiotic Product From New York Health Care, Inc
5. TWi Biotechnology Successfully Completes Patient Recruitment for Phase IIb Trial of AC-201 for the Treatment of Type II Diabetes
6. Kuros Completes Patient Recruitment in a Phase IIb Clinical Trial With KUR-211 for Diabetic Foot Ulcers
7. AMPAC Fine Chemicals Completes Contract Manufacturing Agreement for Smallpox Countermeasure API
8. Peloton Therapeutics Completes $18 Million Series A Financing
9. Sinapis Pharma Completes Phase I Trial
10. MiMedx Group Completes $5,000,000 Private Placement
11. PharmAthene Achieves Anthrax Vaccine Program Milestone and Successfully Completes Technology Transfer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... Francis, WI (PRWEB) November 23, 2014 ... manufacturer and supplier of fine chemical ingredients to ... announced the launch of its new website, Apiscent.com. ... description of Apiscent Labs, clean design, easy navigation, ... that make Apiscent Labs stand out. ...
(Date:11/22/2014)... November 21, 2014 Prominent academics, ... will gather on December 3rd at Genetic Rx, ... series. GeneticRx will take place at the Joseph ... and will discuss the present and future of ... skipping, and gene editing—as well as the treatment ...
(Date:11/22/2014)... IL (PRWEB) November 21, 2014 On ... competitors at the 2014 Emerging Medical Technologies Summit in ... Innovator Awards. Widely regarded among Silicon Valley investors ... medical device innovation, the win also positions Briteseed ... MedTech Innovator competition in 2015 and compete with other ...
(Date:11/22/2014)... 2014  The element of surprise has been a ... strike without warning. Until now, epidemiologists had nothing to ... outbreak, resulting in suboptimal responses to both the H1N1 ... Photo - http://photos.prnewswire.com/prnh/20141121/160242 ... because virus gene structural changes have been found that ...
Breaking Biology Technology:Pioneering Academics and Key Industry Leaders to Discuss Rare Diseases and the Emergence of New Genetic Medicines at Genetic Rx on December 3rd 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3Viruses' Advantage of Surprise is Lost 2
... Practice Statements Were Presented at the AUA Annual,Meeting ... and PLYMOUTH MEETING, Pennsylvania, May 21 /PRNewswire/,-- Galil ... that the,American Urological Association has introduced clinical guidelines ... state,that cryoablation is a treatment option for men ...
... 21 Still River Systems announces,the successful development ... as part of the development of its Monarch250(TM) ... Tesla and conclusively,demonstrates that cyclotrons at this high ... radiation therapy. By increasing the operating,magnetic field, Still ...
... 21 Prime Therapeutics (Prime), a,thought leader ... it has,received accreditation from the National Association ... Internet Pharmacy Practice,Sites(TM) (VIPPS(R)) Program., Prime ... NABP in response to,consumers, concerns regarding the ...
Cached Biology Technology:American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 2American Urological Association (AUA) Clinical Guidelines Recognizes Cryotherapy as Treatment Option for Prostate Cancer Patients 3Still River Systems Announces Operation of the World's Highest Magnetic Field Cyclotron 2Prime Therapeutics Receives VIPPS Accreditation 2
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
(Date:11/4/2014)... In nature, the right amount of death at the ... density, according to new research that could help in ... wildlife stocks. , In a paper in the journal ... University researcher and European colleagues conclude that the kind ... a loss of individuals, or mortality, depends on the ...
(Date:11/4/2014)... 4, 2014) – A majority of Madagascar,s 101 species ... have serious consequences for the rainforests they call home. ... positive impacts lemurs can have on rainforest tree populations, ... could have on the region,s rich biodiversity. , A ... eaten by lemurs. Lemurs in turn disperse the ...
Breaking Biology News(10 mins):Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2When less is more: Death in moderation boosts population density in nature 2Gardeners of Madagascar rainforest at risk 2Gardeners of Madagascar rainforest at risk 3
... Alternative energy is all the rage in major media headlines, ... to a study by researchers from Denmark and The Netherlands ... FASEB Journal, the brain, just like muscles, works harder ... glucose. Not only does this finding help explain why the ...
... Letters, Steve Brusatte, Professor Michael Benton, and colleagues ... not proliferate immediately after they originated, but that their ... by two mass extinctions. "The sheer size ... something special about these animals that preordained them for ...
... future of the gorgeously-decorated fish which throng Australia,s coral reefs ... tourism may well be written in their genes. Of ... are able to re-colonise regions of reef devastated by global ... corals move south, says Dr Line Bay of the ARC ...
Cached Biology News:Mass extinctions and the evolution of dinosaurs 2Fishy future written in the genes 2Fishy future written in the genes 3
... designed to speed up the PCR cloning process ... of sequence or type of polymerase used, are ... are difficult to clone by other PCR cloning ... for potentially detrimental proteins can be cloned and ...
Size & Applications: 20 ml Storage Temp.: -20C Shelf Life: 12 months ...
PCR System for increased fidelity, yield and length of PCR products. Amplifies targets up to 10 kb from human genomic DNA....
Immunogen: Heat inactivated bacterial cells of Salmonella enteriditis,paratyphi and typhimurium Storage: 4 C...
Biology Products: